phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»phkinetica-143Research ArticleИССЛЕДОВАНИЯ ФАРМАКОКИНЕТИКИPHARMACOKINETICS STUDIESМежлекарственные взаимодействия у новых противоэпилептических препаратов: фокус на перампанел и зонисамидDrug-drug interactions in the new antiepileptic drugs: focus to perampanel and zonisamideБелоусовЮрий БорисовичBelousovY. B.belouspharma@mail.ruГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» МЗ РФРоссияRussian National Research Medical University named after N.I. Pirogov Russian Ministry of HealthRussian Federation201409042014015762Copyright © Белоусов Ю.Б., 20142014Белоусов Ю.Б.Belousov Y.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/143

В последние 25 лет наблюдается широкое внедрение новых противоэпилептических препаратов (ПЭП) в клиническую практику. Поскольку часто лечение эпилепсии проводится на протяжении всей жизни, а части пациентам назначается политерапия с другими ПЭП, их межлекарственные взаимодействия являются важным фактором в лечении эпилепсии, что может быть основной терапевтической проблемой. Для новых ПЭП способность к взаимодействию особенно важна, поскольку они чаще всего могут быть назначены только в качестве вспомогательной политерапии, по крайней мере, при первом назначении. Основное фармакокинетическое взаимодействие ПЭП связано с индукцией или торможением печёночных ферментов, в то время как фармакодинамические взаимодействия главным образом могут повлечь синергизм в отношении неблагоприятного воздействия, хотя также существуют примеры противосудорожного синергизма. Настоящая статья подробно описывает фармакокинетические и фармакодинамические взаимодействия новых ПЭП (зонисамид и перампанел) с другими ПЭП.

In the past 25 years, there has been an exponential introduction of new antiepileptic drugs (AEDs) in clinical practice. As is often the treatment of epilepsy carried throughout of life, as part of the patient assigned to polytherapy with other AEDs, their drug-drug interactions are an important factor in the treatment of epilepsy, which can be a major therapeutic challenge. For new AEDs interaction particularly important because they often can only be assigned to an add-on polytherapy, at least the first prescribing. Main pharmacokinetics interaction associated with the induction or inhibition of hepatic enzymes, while mainly pharmacodynamics interaction may result in synergy against adverse effects, although there are also examples of anticonvulsant synergism. This article describes in detail the pharmacokinetics and pharmacodynamics interaction of new AEDs (zonisamide and perampanel) with other AEDs.

перампанелзонисамидфармакокинетикафармакодинамикамежлекарственное взаимодействиеperampanelzonisamidepharmacokineticspharmacodynamicsdrug-drug interactionReferencesBialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat conference (EILAT XI). Epilepsy Res. 2013;103:2-30.Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat conference (EILAT XI). Epilepsy Res. 2013;103:2-30.Browne T.R., Szabo G.K., Kres J., Pylilo R.J. Drug interaction of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol. 1986;26:555.Browne T.R., Szabo G.K., Kres J., Pylilo R.J. Drug interaction of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol. 1986;26:555.Buchanan R.A., Page J.G., French J., Leppik I.E., Padgett C.S. Zonisamide drug interactions. Epilepsia. 1997;38(Supp. 8):107.Buchanan R.A., Page J.G., French J., Leppik I.E., Padgett C.S. Zonisamide drug interactions. Epilepsia. 1997;38(Supp. 8):107.Fuseau E., Templeton D., Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr. 2011;11(Suppl 1):Abs 1.264.Fuseau E., Templeton D., Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr. 2011;11(Suppl 1):Abs 1.264.Hachad H., Ragueneau-Majlessi I., Levy R.H. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24:91-103.Hachad H., Ragueneau-Majlessi I., Levy R.H. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24:91-103.Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N., Ogasawara A., et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52: 1331-40.Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N., Ogasawara A., et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52: 1331-40.Hussein Z., Critchley D., Ferry J., Laurenza A. Population pharmacokinetics of perampanel, a selective, non-competitive AMPA receptor antagonist, in patients with refractory partial onset seizures participating in a randomized, double-blind, placebo-controlled phase III study. Epilepsia. 2011;52(Suppl 6):248-9.Hussein Z., Critchley D., Ferry J., Laurenza A. Population pharmacokinetics of perampanel, a selective, non-competitive AMPA receptor antagonist, in patients with refractory partial onset seizures participating in a randomized, double-blind, placebo-controlled phase III study. Epilepsia. 2011;52(Suppl 6):248-9.Johannessen L.C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-40.Johannessen L.C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-40.Johannessen L.C., Patsalos P.N. Methodologies used to identify and characterize interactions among antiepileptic drugs. Expert Rev Clin Pharmacol. 2012;5:281-92.Johannessen L.C., Patsalos P.N. Methodologies used to identify and characterize interactions among antiepileptic drugs. Expert Rev Clin Pharmacol. 2012;5:281-92.Kochak G.M., Page J.G., Buchanan R.A., Peters R., Padgett C.S. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998;38:166-71.Kochak G.M., Page J.G., Buchanan R.A., Peters R., Padgett C.S. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998;38:166-71.Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-9.Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-9.Laurenza A., Ferry J., Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr. 2012;12(Suppl 1):216-7.Laurenza A., Ferry J., Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr. 2012;12(Suppl 1):216-7.Levy R.H., Ragueneau-Majlessi I., Garnett W.R., Schmerler M., Rosenfeld W., Shah J., et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230-4.Levy R.H., Ragueneau-Majlessi I., Garnett W.R., Schmerler M., Rosenfeld W., Shah J., et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230-4.Minami T., Ieiri I., Ohtsubo K., Hirakawa Y., Ueda K., Higuchi S., et al. Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia. 1994;35:1023-5.Minami T., Ieiri I., Ohtsubo K., Hirakawa Y., Ueda K., Higuchi S., et al. Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia. 1994;35:1023-5.Ojemann L.M., Shastri R.A., Wilensky A.J., Friel P.N., Levy R.H., McLean J.R., et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit. 1986;8:293-6.Ojemann L.M., Shastri R.A., Wilensky A.J., Friel P.N., Levy R.H., McLean J.R., et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit. 1986;8:293-6.Patsalos P.N. Antiepileptic drug interactions - a clinical guide. Berlin: Springer; 2013.Patsalos P.N. Antiepileptic drug interactions - a clinical guide. Berlin: Springer; 2013.Patsalos P.N., Froscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-85.Patsalos P.N., Froscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-85.Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-81.Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-81.Perampanel (Fycompa). Summary of product characteristics. 2012. Eisai Europe Ltd.Perampanel (Fycompa). Summary of product characteristics. 2012. Eisai Europe Ltd.Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-55.Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-55.Perucca E. Pharmacological advantages of antiepileptic drug monotherapy. Epilepsia. 1997;38(Suppl 5):S6-8.Perucca E. Pharmacological advantages of antiepileptic drug monotherapy. Epilepsia. 1997;38(Suppl 5):S6-8.Plosker G.L. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26:1085-96.Plosker G.L. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26:1085-96.Ragueneau-Majlessi I., Levy R.H., Bergen D., Garnett W., Rosenfeld W., Mather G., et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1-11.Ragueneau-Majlessi I., Levy R.H., Bergen D., Garnett W., Rosenfeld W., Mather G., et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1-11.Sackellares J.C., Donofrio P.D., Wagner J.G., Abou-Khalil B., Berent S., Aasved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3- methanesulfonamide) in patients with refractory partial seizures. Epilepsia. 1985;26:206-11.Sackellares J.C., Donofrio P.D., Wagner J.G., Abou-Khalil B., Berent S., Aasved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3- methanesulfonamide) in patients with refractory partial seizures. Epilepsia. 1985;26:206-11.Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185-8.Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185-8.

The authors declare that there are no conflicts of interest present.